Advertisement

Phage antibody library screening for the selection of novel high-affinity human single-chain variable fragment against gastrin receptor: an in silico and in vitro study

  • Sepideh Jalilzadeh-Razin
  • Malihe Mantegi
  • Mohammad R. Tohidkia
  • Yaghub Pazhang
  • Mohammad M. Pourseif
  • Jaleh Barar
  • Yadollah Omidi
Research Article

Abstract

Background

As a membrane G protein coupled receptors (GPCRs) family, gastrin/cholecystokinin-2 receptor (CCK2R) plays a key role in the initiation and development of gastric cancer.

Objectives

Targeting CCK2R by immunotherapeutics such as single-chain variable fragments (scFvs) may provide an effective treatment modality against gastric cancer. Thus, the main objective of this study was to isolate scFvs specific to CCK2R.

Methods

To isolate scFvs specific to the CCK2R, we capitalized on a semi-synthetic diverse phage antibody library (PAL) and a solution-phase biopanning process. The library was panned against a biotinylated peptide of the second extracellular loop (ECL2) of CCK2R. After four rounds of biopanning, the selected soluble scFv clones were screened by enzyme-linked immunosorbent assay (ELISA) and examined for specific binding to the peptide. The selected scFvs were purified using immobilized metal affinity chromatography (IMAC). The binding affinity and specificity of the scFvs were examined by the surface plasmon resonance (SPR), immunoblotting and flow cytometry assays and molecular docking using ZDOCK v3.0.2.

Results

Ten different scFvs were isolated, which displayed binding affinity ranging from 0.68 to 8.0 (nM). Immunoblotting and molecular docking analysis revealed that eight scFvs were able to detect the denatured form of CCK2R protein. Of the isolated scFvs, two scFvs showed high-binding affinity to the human gastric adenocarcinoma AGS cells.

Conclusions

Based on our findings, a couple of the selected scFvs showed markedly high-binding affinity to immobilized CCK2R peptide and CCK2R-overexpressing AGS cells. Therefore, these scFvs are proposed to serve as targeting and/or treatment agents in the diagnosis and immunotherapy of CCK2R-positive tumors.

Graphical abstract

Keywords

Phage display technology Biopanning Single-chain variable fragment Gastric cancer Gastrin receptor Molecular docking 

Abbreviations

CCK2R

Gastrin/cholecystokinin-2 receptor

GPCRs

G protein coupled receptors

scFvs

Single-chain variable fragments

PAL

Phage antibody library

ECL2

Extracellular loop

ELISA

Enzyme-linked immunosorbent assay

IMAC

Immobilized metal affinity chromatography

SPR

Surface plasmon resonance

TM

Transmembrane

ICL

Intracellular loops

ECL

Extracellular loops

MALT

Mucosa-associated lymphoid tissue lymphomas

mAbs

Monoclonal antibodies

PAD

Phage antibody display

Ag

Antigen

g3p

Gene 3 minor coat protein

PDT

Phage display technology

Notes

Acknowledgments

The authors are grateful to the technical support provided by the Research Center for Pharmaceutical Nanotechnology (RCPN) at Tabriz University of Medical Sciences.

Author’s contributions

SJR and MM contributed to the data analysis and interpretation, and MMP was involved in the bioinformatics analysis, YP checked the grammar, MRT, and YO designed and supervised the study, conducted data analysis and interpretation, SJR, JB, MMP, MRT and YO wrote the manuscript.

Funding

The authors are grateful for the financial support provided by the Tabriz University of Medical Sciences (grant# 93003 and 93010).

Compliance with ethical standards

Conflict of interest

The authors of this study declare that they have no conflict of interest.

Supplementary material

40199_2018_233_MOESM1_ESM.jpg (1.1 mb)
ESM 1 (JPG 1.07 MB)
40199_2018_233_MOESM2_ESM.docx (16 kb)
ESM 2 (DOCX 15.5 kb)
40199_2018_233_MOESM3_ESM.docx (13 kb)
ESM 3 (DOCX 13.3 kb)

References

  1. 1.
    Matsueda S, Graham DY. Immunotherapy in gastric cancer. World J Gastroenterol. 2014;20(7):1657–66.  https://doi.org/10.3748/wjg.v20.i7.1657.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Kawakami H, Okamoto I. MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2016;19(3):687–95.  https://doi.org/10.1007/s10120-015-0585-x. CrossRefGoogle Scholar
  3. 3.
    Fahimi F, Tohidkia MR, Fouladi M, Aghabeygi R, Samadi N, Omidi Y. Pleiotropic cytotoxicity of VacA toxin in host cells and its impact on immunotherapy. Bioimpacts. 2017;7(1):59–71.  https://doi.org/10.15171/bi.2017.08.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Fourmy D, Gigoux V, Reubi JC. Gastrin in gastrointestinal diseases. Gastroenterology. 2011;141(3):814–8 e1–3.  https://doi.org/10.1053/j.gastro.2011.07.006.CrossRefPubMedGoogle Scholar
  5. 5.
    Berna MJ, Tapia JA, Sancho V, Jensen RT. Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential. Curr Opin Pharmacol. 2007;7(6):583–92.  https://doi.org/10.1016/j.coph.2007.09.011.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Peeters MC, van Westen GJ, Li Q, AP IJ. Importance of the extracellular loops in G protein-coupled receptors for ligand recognition and receptor activation. Trends Pharmacol Sci. 2011;32(1):35–42.  https://doi.org/10.1016/j.tips.2010.10.001.CrossRefPubMedGoogle Scholar
  7. 7.
    Zhou JJ, Chen ML, Zhang QZ, Hu JK, Wang WL. Coexpression of cholecystokinin-B/gastrin receptor and gastrin gene in human gastric tissues and gastric cancer cell line. World J Gastroenterol. 2004;10(6):791–4.CrossRefGoogle Scholar
  8. 8.
    McWilliams DF, Watson SA, Crosbee DM, Michaeli D, Seth R. Coexpression of gastrin and gastrin receptors (CCK-B and delta CCK-B) in gastrointestinal tumour cell lines. Gut. 1998;42(6):795–8.CrossRefGoogle Scholar
  9. 9.
    Barderas R, Shochat S, Timmerman P, Hollestelle MJ, Martinez-Torrecuadrada JL, Hoppener JW, et al. Designing antibodies for the inhibition of gastrin activity in tumoral cell lines. Int J Cancer. 2008;122(10):2351–9.  https://doi.org/10.1002/ijc.23395.CrossRefPubMedGoogle Scholar
  10. 10.
    Demarest SJ, Hariharan K, Dong J. Emerging antibody combinations in oncology. MAbs. 2011;3(4):338–51.CrossRefGoogle Scholar
  11. 11.
    Koohapitagtam M, Rungpragayphan S, Hongprayoon R, Kositratana W, Sirinarumitr T. Efficient amplification of light and heavy chain variable regions and construction of a non-immune phage scFv library. Mol Biol Rep. 2010;37(4):1677–83.  https://doi.org/10.1007/s11033-009-9583-6.CrossRefPubMedGoogle Scholar
  12. 12.
    Reichert JM. Metrics for antibody therapeutics development. MAbs. 2010;2(6):695–700.CrossRefGoogle Scholar
  13. 13.
    Huang JX, Bishop-Hurley SL, Cooper MA. Development of anti-infectives using phage display: biological agents against bacteria, viruses, and parasites. Antimicrob Agents Chemother. 2012;56(9):4569–82.  https://doi.org/10.1128/AAC.00567-12.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Pansri P, Jaruseranee N, Rangnoi K, Kristensen P, Yamabhai M. A compact phage display human scFv library for selection of antibodies to a wide variety of antigens. BMC Biotechnol. 2009;9:6.  https://doi.org/10.1186/1472-6750-9-6.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Paschke M. Phage display systems and their applications. Appl Microbiol Biotechnol. 2006;70(1):2–11.  https://doi.org/10.1007/s00253-005-0270-9.CrossRefPubMedGoogle Scholar
  16. 16.
    Soltes G, Hust M, Ng KK, Bansal A, Field J, Stewart DI, et al. On the influence of vector design on antibody phage display. J Biotechnol. 2007;127(4):626–37.  https://doi.org/10.1016/j.jbiotec.2006.08.015.CrossRefPubMedGoogle Scholar
  17. 17.
    Whiteaker JR, Zhao L, Frisch C, Ylera F, Harth S, Knappik A, et al. High-affinity recombinant antibody fragments (Fabs) can be applied in peptide enrichment immuno-MRM assays. J Proteome Res. 2014;13(4):2187–96.  https://doi.org/10.1021/pr4009404.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Noppe W, Plieva F, Galaev IY, Pottel H, Deckmyn H, Mattiasson B. Chromato-panning: an efficient new mode of identifying suitable ligands from phage display libraries. BMC Biotechnol. 2009;9:21.  https://doi.org/10.1186/1472-6750-9-21.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NB, Hamid M. scFv antibody: principles and clinical application. Clin Dev Immunol. 2012;2012:980250.  https://doi.org/10.1155/2012/980250.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Cheng LS, Liu AP, Yang JH, Dong YQ, Li LW, Wang J, et al. Construction, expression and characterization of the engineered antibody against tumor surface antigen, p185(c-erbB-2). Cell Res. 2003;13(1):35–48.  https://doi.org/10.1038/sj.cr.7290149.CrossRefPubMedGoogle Scholar
  21. 21.
    Wang Y, Zhang X, Zhang C, Liu Y, Liu X. Isolation of single chain variable fragment (scFv) specific for Cry1C toxin from human single fold scFv libraries. Toxicon: Official Journal of the International Society on Toxinology. 2012;60(7):1290–7.  https://doi.org/10.1016/j.toxicon.2012.08.014. CrossRefGoogle Scholar
  22. 22.
    Huang L, Sato AK, Sachdeva M, Fleming T, Townsend S, Dransfield DT. Discovery of human antibodies against the C5aR target using phage display technology. J Mol Recognit: JMR. 2005;18(4):327–33.  https://doi.org/10.1002/jmr.735. CrossRefPubMedGoogle Scholar
  23. 23.
    Henderikx P, Kandilogiannaki M, Petrarca C. von Mensdorff-Pouilly S, Hilgers JH, Krambovitis E et al. human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma. Cancer Res. 1998;58(19):4324–32.PubMedGoogle Scholar
  24. 24.
    Hawkins RE, Russell SJ, Winter G. Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J Mol Biol. 1992;226(3):889–96.CrossRefGoogle Scholar
  25. 25.
    de Haard HJ, van Neer N, Reurs A, Hufton SE, Roovers RC, Henderikx P, et al. A large non-immunized human fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J Biol Chem. 1999;274(26):18218–30.CrossRefGoogle Scholar
  26. 26.
    Zhang X, Liu Y, Zhang C, Wang Y, Xu C, Liu X. Rapid isolation of single-chain antibodies from a human synthetic phage display library for detection of bacillus thuringiensis (Bt) Cry1B toxin. Ecotoxicol Environ Saf. 2012;81:84–90.  https://doi.org/10.1016/j.ecoenv.2012.04.021.CrossRefPubMedGoogle Scholar
  27. 27.
    Retter I, Althaus HH, Munch R, Muller W. VBASE2, an integrative V gene database. Nucleic Acids Res. 2005;33(Database issue):D671–4.  https://doi.org/10.1093/nar/gki088.CrossRefPubMedGoogle Scholar
  28. 28.
    Eteshola E. Isolation of scFv fragments specific for monokine induced by interferon-gamma (MIG) using phage display. J Immunol Methods. 2010;358(1–2):104–10.  https://doi.org/10.1016/j.jim.2010.04.003.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Johns M, George AJ, Ritter MA. In vivo selection of sFv from phage display libraries. J Immunol Methods. 2000;239(1–2):137–51.CrossRefGoogle Scholar
  30. 30.
    Wu S, Ke A, Doudna JA. A fast and efficient procedure to produce scFvs specific for large macromolecular complexes. J Immunol Methods. 2007;318(1–2):95–101.  https://doi.org/10.1016/j.jim.2006.10.005.CrossRefPubMedGoogle Scholar
  31. 31.
    Sushma K, Vijayalakshmi MA, Krishnan V, Satheeshkumar PK. Cloning, expression, purification and characterization of a single chain variable fragment specific to tumor necrosis factor alpha in Escherichia coli. J Biotechnol. 2010;156(4):238–44.  https://doi.org/10.1016/j.jbiotec.2011.06.039. CrossRefGoogle Scholar
  32. 32.
    Hsu FY, Chou LF, Hor LI, Chang HY. A human single-chain variable fragment targeting to Vibrio vulnificus RtxA toxin. J Microbiol Methods. 2011;84(1):94–100.  https://doi.org/10.1016/j.mimet.2010.11.006.CrossRefPubMedGoogle Scholar
  33. 33.
    Poul MA, Becerril B, Nielsen UB, Morisson P, Marks JD. Selection of tumor-specific internalizing human antibodies from phage libraries. J Mol Biol. 2000;301(5):1149–61.  https://doi.org/10.1006/jmbi.2000.4026.CrossRefPubMedGoogle Scholar
  34. 34.
    Martinez-Torrecuadrada J, Cifuentes G, Lopez-Serra P, Saenz P, Martinez A, Casal JI. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation. Clin Cancer Res. 2005;11(17):6280–90.  https://doi.org/10.1158/1078-0432.CCR-05-0282.CrossRefPubMedGoogle Scholar
  35. 35.
    Kim HY, Wang X, Wahlberg B, Edwards WB. Discovery of hapten-specific scFv from a phage display library and applications for HER2-positive tumor imaging. Bioconjug Chem. 2014;25(7):1311–22.  https://doi.org/10.1021/bc500173f.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Webb B, Sali A. Protein structure modeling with MODELLER. Methods Mol Biol. 2017;1654:39–54.  https://doi.org/10.1007/978-1-4939-7231-9_4.CrossRefPubMedGoogle Scholar
  37. 37.
    Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605–12.  https://doi.org/10.1002/jcc.20084.CrossRefGoogle Scholar
  38. 38.
    Johansson MU, Zoete V, Michielin O, Guex N. Defining and searching for structural motifs using DeepView/Swiss-PdbViewer. BMC Bioinformatics. 2012;13:173.  https://doi.org/10.1186/1471-2105-13-173.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Pourseif MM, Moghaddam G, Daghighkia H, Nematollahi A. Omidi Y. a novel B- and helper T-cell epitopes-based prophylactic vaccine against Echinococcus granulosus. Bioimpacts. 2018;8(1):39–52.  https://doi.org/10.15171/bi.2018.06. CrossRefPubMedGoogle Scholar
  40. 40.
    Dunbrack RL Jr. Rotamer libraries in the 21st century. Curr Opin Struct Biol. 2002;12(4):431–40.CrossRefGoogle Scholar
  41. 41.
    Wiederstein M, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res. 2007;35(Web Server):W407–10.  https://doi.org/10.1093/nar/gkm290.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Eisenberg D, Luthy R, Bowie JU. VERIFY3D: assessment of protein models with three-dimensional profiles. Methods Enzymol. 1997;277:396–404.CrossRefGoogle Scholar
  43. 43.
    Colovos C, Yeates TO. Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci. 1993;2(9):1511–9.  https://doi.org/10.1002/pro.5560020916.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Pourseif MM, Moghaddam G, Naghili B, Saeedi N, Parvizpour S, Nematollahi A, et al. A novel in silico minigene vaccine based on CD4(+) T-helper and B-cell epitopes of EG95 isolates for vaccination against cystic echinococcosis. Comput Biol Chem. 2018;72:150–63.  https://doi.org/10.1016/j.compbiolchem.2017.11.008.CrossRefPubMedGoogle Scholar
  45. 45.
    Lovell SC, Davis IW, Arendall WB 3rd, de Bakker PI, Word JM, Prisant MG, et al. Structure validation by Calpha geometry: phi,psi and Cbeta deviation. Proteins. 2003;50(3):437–50.  https://doi.org/10.1002/prot.10286. CrossRefPubMedGoogle Scholar
  46. 46.
    Chen R, Li L, Weng Z. ZDOCK: an initial-stage protein-docking algorithm. Proteins. 2003;52(1):80–7.  https://doi.org/10.1002/prot.10389.CrossRefPubMedGoogle Scholar
  47. 47.
    Pierce BG, Hourai Y, Weng Z. Accelerating protein docking in ZDOCK using an advanced 3D convolution library. PLoS One. 2011;6(9):e24657.  https://doi.org/10.1371/journal.pone.0024657.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 1995;8(2):127–34.CrossRefGoogle Scholar
  49. 49.
    Reichert JM. Antibodies to watch in 2017. MAbs. 2017;9(2):167–81.  https://doi.org/10.1080/19420862.2016.1269580.CrossRefPubMedGoogle Scholar
  50. 50.
    Majidi J, Barar J, Baradaran B, Abdolalizadeh J, Omidi Y. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies. Hum Antibodies. 2009;18(3):81–100.  https://doi.org/10.3233/hab-2009-0204.CrossRefPubMedGoogle Scholar
  51. 51.
    Mondon P, Dubreuil O, Bouayadi K, Kharrat H. Human antibody libraries: a race to engineer and explore a larger diversity. Front Biosci. 2008;13:1117–29.CrossRefGoogle Scholar
  52. 52.
    Sergeeva A, Kolonin MG, Molldrem JJ, Pasqualini R, Arap W. Display technologies: application for the discovery of drug and gene delivery agents. Adv Drug Deliv Rev. 2006;58(15):1622–54.  https://doi.org/10.1016/j.addr.2006.09.018.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Ebrahimizadeh W, Rajabibazl M. Bacteriophage vehicles for phage display: biology, mechanism, and application. Curr Microbiol. 2014;69(2):109–20.  https://doi.org/10.1007/s00284-014-0557-0.CrossRefPubMedGoogle Scholar
  54. 54.
    Zhao A, Tohidkia MR, Siegel DL, Coukos G, Omidi Y. Phage antibody display libraries: a powerful antibody discovery platform for immunotherapy. Crit Rev Biotechnol. 2016;36(2):276–89.  https://doi.org/10.3109/07388551.2014.958978.CrossRefPubMedGoogle Scholar
  55. 55.
    Khajeh S, Tohidkia MR, Aghanejad A, Mehdipour T, Fathi F, Omidi Y. Phage display selection of fully human antibody fragments to inhibit growth-promoting effects of glycine-extended gastrin 17 on human colorectal cancer cells. Artif Cells Nanomed Biotechnol. 2018:1–9.  https://doi.org/10.1080/21691401.2018.1478846.
  56. 56.
    Fahimi F, Sarhaddi S, Fouladi M, Samadi N, Sadeghi J, Golchin A, et al. Phage display-derived antibody fragments against conserved regions of VacA toxin of helicobacter pylori. Appl Microbiol Biotechnol. 2018;102:6899–913.  https://doi.org/10.1007/s00253-018-9068-4.CrossRefPubMedGoogle Scholar
  57. 57.
    Tohidkia MR, Sepehri M, Khajeh S, Barar J, Omidi Y. Improved soluble ScFv ELISA screening approach for antibody discovery using phage display technology. SLAS Discov. 2017;22(8):1026–34.  https://doi.org/10.1177/2472555217701059.CrossRefPubMedGoogle Scholar
  58. 58.
    Tohidkia MR, Asadi F, Barar J, Omidi Y. Selection of potential therapeutic human single-chain Fv antibodies against cholecystokinin-B/gastrin receptor by phage display technology. BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. 2013;27(1):55–67.  https://doi.org/10.1007/s40259-012-0007-0. CrossRefGoogle Scholar
  59. 59.
    Abdolalizadeh J, Nouri M, Zolbanin JM, Barzegari A, Baradaran B, Barar J, et al. Targeting cytokines: production and characterization of anti-TNF-alpha scFvs by phage display technology. Curr Pharm Des. 2013;19(15):2839–47.CrossRefGoogle Scholar
  60. 60.
    Tohidkia MR, Barar J, Asadi F, Omidi Y. Molecular considerations for development of phage antibody libraries. J Drug Target. 2012;20(3):195–208.  https://doi.org/10.3109/1061186X.2011.611517.CrossRefPubMedGoogle Scholar
  61. 61.
    Abdolalizadeh J, Nouri M, Zolbanin JM, Baradaran B, Barzegari A, Omidi Y. Downstream characterization of anti-TNF-alpha single chain variable fragment antibodies. Hum Antibodies. 2012;21(1–2):41–8.  https://doi.org/10.3233/HAB-2012-0260.CrossRefPubMedGoogle Scholar
  62. 62.
    Hutchings CJ, Koglin M, Marshall FH. Therapeutic antibodies directed at G protein-coupled receptors. MAbs. 2010;2(6):594–606.  https://doi.org/10.4161/mabs.2.6.13420.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Kmiecik S, Jamroz M, Kolinski M. Structure prediction of the second extracellular loop in G-protein-coupled receptors. Biophys J. 2014;106(11):2408–16.  https://doi.org/10.1016/j.bpj.2014.04.022.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Silacci M, Brack S, Schirru G, Marlind J, Ettorre A, Merlo A, et al. Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics. 2005;5(9):2340–50.  https://doi.org/10.1002/pmic.200401273.CrossRefPubMedGoogle Scholar
  65. 65.
    Lobova D, Cizek A, Celer V. The selection of single-chain Fv antibody fragments specific to Bhlp 29.7 protein of Brachyspira hyodysenteriae. Folia Microbiol. 2008;53(6):517–20.  https://doi.org/10.1007/s12223-008-0081-3.CrossRefGoogle Scholar
  66. 66.
    Villa A, Lovato V, Bujak E, Wulhfard S, Pasche N, Neri D. A novel synthetic naive human antibody library allows the isolation of antibodies against a new epitope of oncofetal fibronectin. MAbs. 2011;3(3):264–72.CrossRefGoogle Scholar
  67. 67.
    Zhang Y, Pool C, Sadler K, Yan HP, Edl J, Wang X, et al. Selection of active ScFv to G-protein-coupled receptor CCR5 using surface antigen-mimicking peptides. Biochemistry. 2004;43(39):12575–84.  https://doi.org/10.1021/bi0492152.CrossRefPubMedGoogle Scholar
  68. 68.
    Gupta A, Decaillot FM, Gomes I, Tkalych O, Heimann AS, Ferro ES, et al. Conformation state-sensitive antibodies to G-protein-coupled receptors. J Biol Chem. 2007;282(8):5116–24.  https://doi.org/10.1074/jbc.M609254200. CrossRefPubMedGoogle Scholar
  69. 69.
    Koide A, Koide S. Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain. Methods Mol Biol. 2007;352:95–109.  https://doi.org/10.1385/1-59745-187-8:95. CrossRefPubMedGoogle Scholar
  70. 70.
    Vazquez-Lombardi R, Phan TG, Zimmermann C, Lowe D, Jermutus L, Christ D. Challenges and opportunities for non-antibody scaffold drugs. Drug Discov Today. 2015;20(10):1271–83.  https://doi.org/10.1016/j.drudis.2015.09.004.CrossRefPubMedGoogle Scholar
  71. 71.
    Moghimi SM, Rahbarizadeh F, Ahmadvand D, Parhamifar L. Heavy chain only antibodies: a new paradigm in personalized HER2+ breast Cancer therapy. BioImpacts : BI. 2013;3(1):1–4.  https://doi.org/10.5681/bi.2013.009. CrossRefPubMedGoogle Scholar
  72. 72.
    Liebman MA, Williams BR, Daley KM, Sharon J. Generation and preliminary characterization of an antibody library with preferential reactivity to human colorectal cancer cells as compared to normal human blood cells. Immunol Lett. 2004;91(2–3):179–88.  https://doi.org/10.1016/j.imlet.2003.12.002.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Research Center for Pharmaceutical Nanotechnology, Biomedicine InstituteTabriz University of Medical SciencesTabrizIran
  2. 2.Islamic Azad University of UrmiaUrmiaIran
  3. 3.Department of Biochemistry, Faculty of Veterinary MedicineUrmia UniversityUrmiaIran
  4. 4.Department of Pharmaceutics, Faculty of PharmacyTabriz University of Medical SciencesTabrizIran

Personalised recommendations